An enhanced risk-group stratification system for more practical prognostication of clinically malignant gastrointestinal stromal tumors

International Journal of Clinical Oncology

Volumn 12, Issue 5, 2007, Pages 369-374

  Takahashi, Tsuyoshi ^a   Nakajima, Kiyokazu ^a   Nishitani, Akiko ^a   Souma, Yoshihito ^a   Hirota, Seiichi ^b   Sawa, Yoshiki ^a   Nishida, Toshirou ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Adjuvant therapy; Clinically malignant group; Gastrointestinal stromal tumor; Imatinib; Risk group stratification system

Indexed keywords

CD34 ANTIGEN; IMATINIB; STEM CELL FACTOR;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER RECURRENCE; CARCINOGENESIS; DISEASE FREE SURVIVAL; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MITOSIS; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PIPERAZINES; PROGNOSIS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 35348871015     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-007-0705-7     Document Type: Article

References (22)

1. S Hirota K Isozaki Y Moriyama 1998 Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors Science 279 577 580
2. T Nishida S Hirota M Taniguchi 1998 Familial gastrointestinal stromal tumours with germline mutation of the kit gene Nat Genet 19 323 324
3. S Hirota A Ohashi T Nishida 2003 Gain-of-function mutation of platelet-derived growth factor receptor α gene in gastrtointestinal stromal tumors Gastroenterology 125 660 667
4. MC Heinrich CL Corless A Duensing 2003 PDGFRA activating mutations in gastrointestinal stromal tumors Science 299 708 710
5. MC Heinrich DJ Griffith BJ Drucker 2000 Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor Blood 96 925 932
6. GD Demetri M von Meheren CD Blanlke 2002 Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 472 480
7. J Verweiji A van Osterom JY Blay 2003 Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: Results from an EORTC Soft Tissue and Bone Sarcoma Group phase - study Eur J Cancer 39 2006 2011
8. Nishida T, Shirao K, Yamao K, et al. (2004) Preliminary results of the phase clinical trial of imatinb mesylate for advanced gastrointestinal stromal tumors in Japan. In: Kitamura Y, Miettinenn M, Hirota S, Kanakura Y (eds) GANN monograph on cancer research. Tokyo, pp. 151-157
9. MC Heinrich CL Corless DG Demetri 2003 Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor J Clin Oncol 22 4342 4349
10. J Veweiji PG Casali J Zalcberg 2004 Progression-free survival in gastrointestinal stromal tumors with high-dose imatinib Lancet 364 1127 1134
11. C Fletcher J Berman C Corless 2002 Diagnosis of gastrointestinal stromal tumors: a consensus approach Hum Pathol 33 459 465
12. B Nilsson P Bümming JM Meis-Kindblom 2005 Gastrointestinal stromal tumors: the incidence, the prevalence, clinical course and prognostication in the preimatinib mesylate era - a population-based study in western Sweden Cancer 103 821 829
13. M Miettinen W El-Rifai LH Sobin 2002 Evaluation of malignancy and prognosis of gastrointestinal stromal tomors Hum Pathol 33 478 483
14. K Yokoi N Tanaka S Kyono 2005 A study of histopathological assessment criteria for assessing malignancy of gastrointestinal stromal tumor, from a clinical standpoint J Gastroenterol 40 467 473
15. Nishimura J, Nakajima K, Ohmori T, et al. (2006) Surgical strategy for gastric gastrointestinal stromal tumors: laparoscopic vs open resection. Surg Endosc (2007) 21:875-878. (Published online 16 Dec 2006)
16. K Isozaki B Terris J Belghiti 2000 Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors Am J Pathol 157 1581 1585
17. S Hirota T Nishida K Isozaki 2002 Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene Gastroenterology 122 1493 1499
18. H Maeda A Yamagata S Nishikawa 1992 Requirement of c-kit for development of intestinal pacemaker system Development 116 369 375
19. IR Lai RH Hu K Chang 2005 Is imatinib justified as an adjuvant chemotherapy for patients with recurrent gastrointestinal stromal tumors Hepatogastroenterology 52 826 828
20. RS Benjamin CD Blanke JY Blay 2006 Management of gastrointestinal stromal tumors in the imatinib era: selected case studies Oncologist 11 9 20
21. BL Eisenberg I Judson 2004 Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy Ann Surg Oncol 11 465 475
22. TJ Wu LY Lee CN Yeh 2006 Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate BMC Gastroenterol 6 1 8